Juvenile myoclonic epilepsy: Under-appreciated and under-diagnosed

Postgraduate Medical Journal

Volumn 79, Issue 928, 2003, Pages 78-80

  Renganathan, R ^a,b   Delanty, N ^b  

^a University College Cork and INFANT Centre   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; HUMAN; MYOCLONUS EPILEPSY; PATHOGENESIS; PROGNOSIS; REVIEW; TENDON REFLEX; TONIC CLONIC SEIZURE; VAGUS NERVE STIMULATION;

ADOLESCENT; ANTICONVULSANTS; CHILD; DIAGNOSIS, DIFFERENTIAL; HUMANS; MYOCLONIC EPILEPSY, JUVENILE; PROGNOSIS;

EID: 0037293049     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.928.78     Document Type: Review

References (21)

1. Genton P, Gelisse P. Juvenile myoclonic epilepsy. Arch Neurol 2001;58:1487-90.
2. Janz D, Durner M. Juvenile myoclonic epilepsy. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997: 2389-400.
3. Sander T, Bockenkamp B, Hildmann T, et al. Refined mapping of the epilepsy susceptibility locus EJM1 on chromosome 6. Neurology 1997;49:842-7.
4. Durner M, Shinnar S, Resor SR, et al. No evidence for a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. Am J Med Genet (Neuropsychiatric Genetics) 2000;96:49-52.
5. Meencke HJ, Janz D. The significance of microdysgenesia in primary generalised epilepsy: an answer to the considerations of Lyon and Gastaut. Epilepsia 1985;26:368-71.
6. Panyiotopoulos CP, Obeid T, Tahan R. Juvenile myoclonic epilepsy: a 5 year prospective study. Epilepsia 1994;35:285-96.
7. Delgado-Escueta AV, Serratosa JM, Medina MT. Juvenile myoclonic epilepsy. In: Wylie E, ed. The treatment of epilepsy: principles and practice. 2nd Ed. Baltimore: Williams & Wilkins, 1996: 484-51.
8. Gruenwald Ra, Chroni E, Panayiotopoulos CP. Delayed diagnosis of juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 1992;55:497-9.
9. Lancman ME, Asconape JJ, Penry JK. Clinical and EEG asymmetries in juvenile myoclonic epilepsy. Epilepsia 1994;35:302-6.
10. Alibert V, Grunewald A, Panayiotopoulos CP, et al. Focal electroencephalographic abnormalities in juvenile myoclonic epilepsy. Epilepsia 1994;35:297-301.
11. Salas-Pung J, Tunon A, Diaz M, et al. Somatosensory evoked potentials in juvenile myoclonic epilepsy. Epilepsia 1992;33:527-30.
12. Woermann FG, Free SL, Koepp MJ, et al. Abnormal cerebral structure in juvenile myoclonic epilepsy demonstrated with voxel-based analysis of MRI. Brain 1999;122:2101-7.
13. Savic I, Lekvall A, Greitz D, et al. MR Spectroscopy shos reduced frontal lobe concentrations of N-acetyl aspartate in patients with juvenile myoclonic epilepsy. Epilepsia 2000;41:290-6.
14. 18FDG-PET study. Neurology 1996;47:1203-12.
15. Genton P, Gelisse P, Thomas P, et al. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9.
16. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5:149-51.
17. Biraben A, Allain H, Scarabin JM., et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55:1758.
18. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:1330.
19. Smith K, Bettz T. The effect of add on therapy with leveteracetam (UCBL059) on patients with resistant juvenile myoclonic epilepsy (abstract). Fourth Eilat Conference on New Antiepileptic Drugs 1998: 57.
20. Disabato JA, Barnhurst RF, Levisohn PM. Efficacy of vagus nerve stimulation in young children with generalized epilepsies (abstract). Epilepsia 2001;42:171.
21. Gelisse P, Genton P, Thora P, et al. Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 2001;70:240-3.